Identification of risk factors and development of a predictive nomogram for sarcopenia in Alzheimer's disease
Alzheimer's & Dementia · 2025
DOI: 10.1002/alz.14503 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Sihui Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Sarcopenia, Nomograms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Cadre Health Project of Sichuan Province, the Fund Project of Sichuan Provincial Department of Science and Technology, the National Key Research and Development Program of China Program.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Sarcopenia, with its complex diagnostic process, is a likely independent predictor of poor prognosis in patients with Alzheimer's disease (AD). However, research on the clinical characteristics and biomarkers of AD patients with sarcopenia (ADSA) is limited. METHODS This study included 180 ADSA and 188 AD patients without sarcopenia (ADNSA), and evaluated demographics, cognitive function, motor capacity, emotional state, and daily living abilities. RESULTS ADSA patients were older, with worse motor and cognitive functions, more severe depression, poorer social functioning, and lower daily living abilities compared to ADNSA patients. Multivariate regression identified age, low Frailty Rating Scale (FRS) scores, low serum albumin level, and low creatinine/cystatin C ratio (CCR) as risk factors for sarcopenia. A nomogram model based on these indicators demonstrated high discriminative power and clinical utility. DISCUSSION Sarcopenia significantly affects AD patients’ various functions. The nomogram model aids in the early detection of and personalized interventions for sarcopenia in AD. Highlights Sarcopenia is a risk factor for Alzheimer's disease (AD), and the coexistence of sarcopenia affects various functions and quality of life in patients with AD. Serum albumin and Frailty Rating Scale (FRS) scores are significantly associated with both sarcopenia and cognitive assessment indicators in AD patients with sarcopenia (ADSA). The combined sarcopenia nomogram model with indexes of age at diagnosis, creatinine/cystatin C ratio (CCR), FRS score, and albumin levels can aid in effectively identifying and personalizing interventions for sarcopenia in the AD population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Xueping Chen
Förderung
- the Cadre Health Project of Sichuan Province
- the Fund Project of Sichuan Provincial Department of Science and Technology
- the National Key Research and Development Program of China Program
- the Sichuan Science and Technology Program
- the Sci-Tech Innovation 2023 "Brain Science and Brain-like Research"
- Connecticut Institute for the Brain and Cognitive Sciences
- Sichuan Province Science and Technology Support Program
- Science and Technology Department of Sichuan Province
Zitieren
APA
Chen, S., Ou, R., Wei, Q., Fu, J., Zhao, B., Chen, X., & Shang, H. (2025). Identification of risk factors and development of a predictive nomogram for sarcopenia in Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14503
Vancouver
Chen S, Ou R, Wei Q, Fu J, Zhao B, Chen X, et al. Identification of risk factors and development of a predictive nomogram for sarcopenia in Alzheimer's disease. Alzheimer's & Dementia. 2025. doi:10.1002/alz.14503
BibTeX
@article{Chen2025,
author = {Chen, Sihui and Ou, Ruwei and Wei, Qianqian and Fu, Jiajia and Zhao, Bi and Chen, Xueping and Shang, Huifang},
title = {Identification of risk factors and development of a predictive nomogram for sarcopenia in Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2025},
doi = {10.1002/alz.14503}
}
EUVIMED